Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 17Ovarian Neoplasms 16Fallopian Tube Neoplasms 12Neoplasm Metastasis 10Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Neoplasms 7Endometrial Neoplasms 6Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neuroendocrine Tumors 3Metastatic Castration-resistant Prostate Cancer 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Sarcoma 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Osteosarcoma 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × olaparib × 90 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡